绘图 340B 资金通过合同药房流动
Anthony M DiGiorgio1,2, Parisa Jahangirizadeh3, Deborah Williams4
1The University of California, San Francisco, CA, USA.
概括
340B的药物定价计划是为了提高药物价格.
科学领域:
- 卫生经济学 卫生经济学
- 制药政策 制药政策
- 医疗保健管理的管理
背景情况:
- 340B药品定价计划 (340B) 旨在降低安全网提供商的药品成本.
- 计划的扩展和合同药房的使用引起了人们对其当前影响和功能的担忧.
研究的目的:
- 分析当代340B计划中的资金流动.
- 识别利转移和与计划最初意图不一致的情况,重点关注合同药房和PBM.
主要方法:
- 在340B生态系统中的金融交易的详细映射.
- 分析利激励和资金流动,涉及覆盖实体,合同药房,TPA和PBM.
主要成果:
- 被覆盖的实体从340B种药物中获得了显著的利,没有重新投资到服务不足的人群的授权.
- 合同药房和TPA增加了复杂性和转移和重复折扣的风险.
- 垂直集成的PBM药房连锁店获得了相当大的收入.
结论:
- 目前的340B计划显示了利激励和患者护理目标之间的错位.
- 需要进行立法和行政改革,以重新将340B计划的重点放在预期的受益者上:低收入和弱势患者.
关键词:
340B 340B 340B是340B的意思,就是说它是340B的意思,它是340B的意思.卫生政策 卫生政策合同药房 合同药房 合同药房被覆盖的实体是被覆盖的实体.药品价格的设定 药品价格的设定药房福利管理员 药房福利管理员第三方管理员第三方管理员更多相关视频
09:58Spatial Quantification of Drugs in Pulmonary Tuberculosis Lesions by Laser Capture Microdissection Liquid Chromatography Mass Spectrometry LCM-LC/MS
Published on: April 18, 2018
9.4K
16:19Heterotopic Auxiliary Rat Liver Transplantation With Flow-regulated Portal Vein Arterialization in Acute Hepatic Failure
Published on: September 13, 2014
13.2K
相关概念视频
Drug Distribution: Tissue Binding
3.8K
Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
For...
3.8K
Drug Products: Biologics, Biosimilars and Interchangeables
214
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
214
Drug Biotransformation: Overview
3.5K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
3.5K
Drug Biotransformation: Overview
2.4K
Biotransformation, also known as drug metabolism, is a vital physiological process that chemically alters drugs, facilitating their elimination from the body and terminating their action. This process involves two main phases: phase I and phase II reactions. Phase I reactions, including oxidation, reduction, and hydrolysis, introduce or unmask polar functional groups on the drug molecule, thereby increasing its water solubility. By enhancing water solubility, the drug becomes more hydrophilic...
2.4K
Drug Elimination by Renal Route: Tubular Secretion
3.2K
Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
3.2K
Hepatic Drug Excretion: Enterohepatic Cycling
2.5K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
2.5K
